Mylan underpayment on EpiPen could exceed proposed settlement -study

NEW YORK (Reuters) - The amount that drugmaker Mylan NV avoided paying the U.S. government in Medicaid rebates for its EpiPen emergency allergy treatment since 2007 likely exceeds a proposed $465 million settlement the company announced in October, according to a study by private drug pricing experts published on Monday.

from Reuters: U.S. http://ift.tt/2naCi3A